BACKGROUND: The rise in dengue fever cases and the absence of dengue vaccines will likely cause governments to consider various types of effective means for controlling the disease. Given strong public interests in potential dengue vaccines, it is essential to understand the private economic benefits of dengue vaccines for accelerated introduction of vaccines into the public sector program and private markets of high-risk countries. METHODOLOGY/PRINCIPAL FINDINGS: A contingent valuation study for a hypothetical dengue vaccine was administered to 400 households in a multi-country setting: Vietnam, Thailand, and Colombia. All respondents received a description of the hypothetical dengue vaccine scenarios of 70% or 95% effectiveness for 10 or 30 years with a three dose series. Five price points were determined after pilot tests in order to reflect different local situations such as household income levels and general perceptions towards dengue fever. We adopted either Poisson or negative binomial regression models to calculate average willingness-to-pay (WTP), as well as median WTP. We found that there is a significant demand for dengue vaccines. The parametric median WTP is $26.4 ($8.8 per dose) in Vietnam, $70.3 ($23.4 per dose) in Thailand, and $23 ($7.7 per dose) in Colombia. Our study also suggests that respondents place more value on vaccinating young children than school age children and adults. CONCLUSIONS/SIGNIFICANCE: Knowing that dengue vaccines are not yet available, our study provides critical information to both public and private sectors. The study results can be used to ensure broad coverage with an affordable price and incorporated into cost benefit analyses, which can inform prioritization of alternative health interventions at the national level.
BACKGROUND: The rise in dengue fever cases and the absence of dengue vaccines will likely cause governments to consider various types of effective means for controlling the disease. Given strong public interests in potential dengue vaccines, it is essential to understand the private economic benefits of dengue vaccines for accelerated introduction of vaccines into the public sector program and private markets of high-risk countries. METHODOLOGY/PRINCIPAL FINDINGS: A contingent valuation study for a hypothetical dengue vaccine was administered to 400 households in a multi-country setting: Vietnam, Thailand, and Colombia. All respondents received a description of the hypothetical dengue vaccine scenarios of 70% or 95% effectiveness for 10 or 30 years with a three dose series. Five price points were determined after pilot tests in order to reflect different local situations such as household income levels and general perceptions towards dengue fever. We adopted either Poisson or negative binomial regression models to calculate average willingness-to-pay (WTP), as well as median WTP. We found that there is a significant demand for dengue vaccines. The parametric median WTP is $26.4 ($8.8 per dose) in Vietnam, $70.3 ($23.4 per dose) in Thailand, and $23 ($7.7 per dose) in Colombia. Our study also suggests that respondents place more value on vaccinating young children than school age children and adults. CONCLUSIONS/SIGNIFICANCE: Knowing that dengue vaccines are not yet available, our study provides critical information to both public and private sectors. The study results can be used to ensure broad coverage with an affordable price and incorporated into cost benefit analyses, which can inform prioritization of alternative health interventions at the national level.
Authors: K Okanurak; S Sornmani; R Mas-ngammueng; P Sitaputra; S Krachangsang; J Limsomboon Journal: Southeast Asian J Trop Med Public Health Date: 1997-06 Impact factor: 0.267
Authors: Ziaul Islam; Brian Maskery; Andrew Nyamete; Mark S Horowitz; Mohammad Yunus; Dale Whittington Journal: Health Policy Date: 2007-09-05 Impact factor: 2.980
Authors: Samir Bhatt; Peter W Gething; Oliver J Brady; Jane P Messina; Andrew W Farlow; Catherine L Moyes; John M Drake; John S Brownstein; Anne G Hoen; Osman Sankoh; Monica F Myers; Dylan B George; Thomas Jaenisch; G R William Wint; Cameron P Simmons; Thomas W Scott; Jeremy J Farrar; Simon I Hay Journal: Nature Date: 2013-04-07 Impact factor: 49.962
Authors: Julia E Painter; Michael E von Fricken; Suyane Viana de O Mesquita; Ralph J DiClemente Journal: Hum Vaccin Immunother Date: 2018-02-15 Impact factor: 3.452
Authors: Carlos E Carpio; Oscar Sarasty; Darren Hudson; Anthony Macharia; Mumina Shibia Journal: Hum Vaccin Immunother Date: 2021-07-09 Impact factor: 4.526
Authors: Jung-Seok Lee; Vittal Mogasale; Jacqueline K Lim; Mabel Carabali; Chukiat Sirivichayakul; Dang Duc Anh; Kang-Sung Lee; Vu Dinh Thiem; Kriengsak Limkittikul; Le Huu Tho; Ivan D Velez; Jorge E Osorio; Pornthep Chanthavanich; Luiz J da Silva; Brian A Maskery Journal: PLoS Negl Trop Dis Date: 2015-06-24
Authors: Jung-Seok Lee; Vittal Mogasale; Jacqueline K Lim; Mabel Carabali; Chukiat Sirivichayakul; Dang Duc Anh; Kang-Sung Lee; Vu Dinh Thiem; Kriengsak Limkittikul; Le Huu Tho; Ivan D Velez; Jorge E Osorio; Pornthep Chanthavanich; Luiz J da Silva; Brian A Maskery Journal: PLoS Negl Trop Dis Date: 2015-09-17
Authors: Thomas J Hladish; Carl A B Pearson; Dennis L Chao; Diana Patricia Rojas; Gabriel L Recchia; Héctor Gómez-Dantés; M Elizabeth Halloran; Juliet R C Pulliam; Ira M Longini Journal: PLoS Negl Trop Dis Date: 2016-05-26